Watchlist

Watchlist
Aldeyra Therapeutics, Inc. (ALDX)
Aldeyra Therapeutics, Inc. (ALDX)
This ROTY Pilot Position Has Several Reasons To Run Higher
Aldeyra Therapeutics ( ALDX ) has fallen by 17% since my initial write-up from last September where I noted the firm appears to be making a successful transition into a late-stage story. Figure 1: ALDX daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) …
ROTY Edition 1 Volume 81: We Have A Launch Date!
Welcome to the 81st entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril…
Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
LEXINGTON, Mass. , Feb. 21, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced thatthe results of the …
What's Next For Aldeyra Therapeutics?
"Every man I meet wants to protect me. I can't figure out what from." - Mae West Today we revisit Aldeyra Therapeutics ( ALDX ). This is a " Tier 4 " Busted IPO we have not covered in some time. Company Overview Aldeyra Therapeuticsis an Lexington, Massachusetts based clinical stag…
Your Daily Pharma Scoop: Achaogen Update, Seattle Genetics Acquires Cascadian, Vical Announces Restructuring
Market update : Good morning, fellow investors. After the 21% gains last year, NBI kicked off the New Year on a very positive note. On the final trading day of the first month of 2018, the index is already up more than 9%. The gains have been partly driven by strong performance in the broader…
Mid-stage study underway for Aldeyra's reproxalap in dry eye disease
The first patient has been enrolled in a Phase 2b clinical trial assessing Aldeyra Therapeutics' ( ALDX -0.7% ) lead candidate reproxalap for the topical treatment of dry eye disease (DED). More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Read more …
ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades
Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril…
Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial
LEXINGTON, Mass. , Jan. 30, 2018 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinic…
Aldeyra Therapeutics: Multiple Clinical Catalysts Make This A Buy
Shares of Aldeyra Therapeutics ( ALDX ) have finished just barely in the green since my initial article in which I noted that the company was transitioning into a promising late-stage story. This was followed by a "Buy the Secondary" piece , in which I outlined five reasons why readers shou…
Premarket analyst action - healthcare
Zynerba Pharmaceuticals (NASDAQ: ZYNE ), BioDelivery Sciences (NASDAQ: BDSI ), Aldeyra Therapeutics (NASDAQ: ALDX ) and Aerie Pharmaceuticals (NASDAQ: AERI ) all initiated with Buy ratings at Seaport Global Securities. More news on: Zynerba Pharmaceuticals, BioDelivery Sciences Internation…
Aldeyra Therapeutics, Inc. (ALDX)